JP2021527084A5 - - Google Patents

Info

Publication number
JP2021527084A5
JP2021527084A5 JP2020568956A JP2020568956A JP2021527084A5 JP 2021527084 A5 JP2021527084 A5 JP 2021527084A5 JP 2020568956 A JP2020568956 A JP 2020568956A JP 2020568956 A JP2020568956 A JP 2020568956A JP 2021527084 A5 JP2021527084 A5 JP 2021527084A5
Authority
JP
Japan
Prior art keywords
terlipressin
acetate
amount
provides
pharmaceutical composition
Prior art date
Application number
JP2020568956A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019239386A5 (https=
JP7523775B2 (ja
JP2021527084A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/055004 external-priority patent/WO2019239386A1/en
Publication of JP2021527084A publication Critical patent/JP2021527084A/ja
Publication of JP2021527084A5 publication Critical patent/JP2021527084A5/ja
Publication of JPWO2019239386A5 publication Critical patent/JPWO2019239386A5/ja
Priority to JP2024065219A priority Critical patent/JP2024086898A/ja
Application granted granted Critical
Publication of JP7523775B2 publication Critical patent/JP7523775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020568956A 2018-06-15 2019-06-14 テルリプレシン組成物及びその使用 Active JP7523775B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024065219A JP2024086898A (ja) 2018-06-15 2024-04-15 テルリプレシン組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685447P 2018-06-15 2018-06-15
US62/685,447 2018-06-15
PCT/IB2019/055004 WO2019239386A1 (en) 2018-06-15 2019-06-14 Terlipressin compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024065219A Division JP2024086898A (ja) 2018-06-15 2024-04-15 テルリプレシン組成物及びその使用

Publications (4)

Publication Number Publication Date
JP2021527084A JP2021527084A (ja) 2021-10-11
JP2021527084A5 true JP2021527084A5 (https=) 2022-06-17
JPWO2019239386A5 JPWO2019239386A5 (https=) 2022-06-17
JP7523775B2 JP7523775B2 (ja) 2024-07-29

Family

ID=67742882

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020568956A Active JP7523775B2 (ja) 2018-06-15 2019-06-14 テルリプレシン組成物及びその使用
JP2024065219A Pending JP2024086898A (ja) 2018-06-15 2024-04-15 テルリプレシン組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024065219A Pending JP2024086898A (ja) 2018-06-15 2024-04-15 テルリプレシン組成物及びその使用

Country Status (9)

Country Link
US (1) US11931398B2 (https=)
EP (1) EP3806823A1 (https=)
JP (2) JP7523775B2 (https=)
CN (1) CN112969449B (https=)
BR (1) BR112020025380A2 (https=)
CA (1) CA3103215A1 (https=)
MX (1) MX2020013389A (https=)
TW (1) TW202003548A (https=)
WO (1) WO2019239386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220080023A1 (en) * 2018-12-21 2022-03-17 Arecor Limited Novel composition
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN114177147B (zh) * 2021-12-15 2023-05-23 福建省闽东力捷迅药业股份有限公司 一种注射用特利加压素的制备方法以及制得的注射用特利加压素
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1244794A (zh) * 1997-11-06 2000-02-16 奥尔班公司 用于药物释放的稳定的干燥药物组合物及其制备方法
RU2415149C2 (ru) * 2006-02-10 2011-03-27 Ферринг Б.В. Пептидные соединения
CN102068685A (zh) * 2010-04-09 2011-05-25 深圳翰宇药业股份有限公司 一种特利加压素制剂及其制备方法
CN102440957B (zh) 2011-12-16 2013-09-25 深圳市健元医药科技有限公司 醋酸特利加压素鼻腔喷雾剂及其制备方法
CN104334117A (zh) 2012-01-26 2015-02-04 恩多沙普公司 用远端和/或近端控制来输送管腔闭塞装置的系统、装置和方法
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
CN105592855A (zh) * 2013-04-26 2016-05-18 拉卓拉药物公司 用于治疗肾衰竭的组合物和方法
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN106188218B (zh) * 2016-07-14 2018-11-23 江苏诺泰澳赛诺生物制药股份有限公司 一种提高多肽原料药稳定性的方法
GB201721846D0 (en) 2017-12-22 2018-02-07 Arecor Ltd Novel composition
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형

Similar Documents

Publication Publication Date Title
JP2021527084A5 (https=)
ES2315123B1 (es) Composiciones farmaceuticas estables de tetraciclinas en solucion, procedimiento para su obtencion y sus usos.
JP2018138578A5 (https=)
ES2145115T4 (es) Composiciones inyectables a base de derivados de taxanos.
JP7093669B2 (ja) 即効型インスリン組成物
JP2013511522A (ja) ダプトマイシン製剤
ES2961458T3 (es) Composición líquida estable que comprende toxina botulínica
JP2015527402A5 (https=)
JP2010530846A (ja) 高温で安定なペプチド製剤
ES2336034T3 (es) Composiciones de diclofenaco inyectables estables.
JP2018528242A5 (https=)
JP2015231997A5 (https=)
RU2015132431A (ru) Составы, содержащие антитела
ES2966895T3 (es) Formulaciones de vacunas de glicoconjugados de expec
JPS6021570B2 (ja) ド−パ類の高濃度製剤の製法
JP2016503058A5 (https=)
BRPI0616300A2 (pt) formulaÇço aquosa de hfsh
JP2022097600A (ja) 抗ＴＮＦα抗体の液状製剤
JP2024086898A (ja) テルリプレシン組成物及びその使用
JP2020511443A5 (https=)
BR112012029212A2 (pt) formulação de paracetamol injetável pronta para o uso estável
WO2022135395A1 (zh) 稳定的抗体制剂及其制备方法和应用
JP2019537589A5 (https=)
JP2020511440A5 (https=)
US10933019B2 (en) Liquid formulations of daptomycin